Specify a stock or a cryptocurrency in the search bar to get a summary
Biomerieux SA
EYWNbioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA. Address: 376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280
Analytics
WallStreet Target Price
104.21 EURP/E ratio
31.7579Dividend Yield
0.77 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EYWN
Dividend Analytics EYWN
Dividend growth over 5 years
150 %Continuous growth
–Payout Ratio 5 years average
17 %Dividend History EYWN
Stock Valuation EYWN
Financials EYWN
Results | 2019 | Dynamics |